About GenEp
GenEp is a company based in Charlottesville (United States) founded in 2021. GenEp has raised $10.4 million across 3 funding rounds from investors including University of Virginia, 3B Future Health Fund and Kids Connect Charitable Fund. GenEp operates in a competitive market with competitors including Marinus Pharma, Arvelle Therapeutics, ORPHELIA Pharma, EpilepsyGTx and Corlieve Therapeutics, among others.
- Headquarter Charlottesville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.4 M (USD)
in 3 rounds
-
Latest Funding Round
$4 M (USD), Series A
Jul 17, 2024
-
Investors
University of Virginia
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of GenEp
GenEp has successfully raised a total of $10.4M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GenEp
GenEp has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include University of Virginia, 3B Future Health Fund and Kids Connect Charitable Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage healthcare investments are made by 3B Future Health Fund.
|
Locked | Locked | Locked | |
|
Angelini Ventures is focused on investing in BioTech and Digital Health.
|
Locked | Locked | Locked | |
|
Multiple courses and degrees across diversified streams are offered.
|
Locked | Locked | Locked |
Investor details for GenEp
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenEp
Investment portfolio details for GenEp
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GenEp
Detailed financials for GenEp
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genep Comparisons
Peer comparison for GenEp
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GenEp
GenEp operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Marinus Pharma, Arvelle Therapeutics, ORPHELIA Pharma, EpilepsyGTx and Corlieve Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics to treat seizure disorders
|
|
| Locked | Locked | Locked |
Small molecule therapies are developed for partial-onset seizures treatment.
|
|
| Locked | Locked | Locked |
Therapies for pediatric neurology, oncology, and hematology are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for focal refractory epilepsy are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for neurological disorders are developed using AAV gene delivery.
|
|
| Locked | Locked | Locked |
Develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions.
|
Detailed competitors of GenEp
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genep
Complete news archive for GenEp
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenEp
GenEp was founded in 2021.
GenEp is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Andrew J Krouse is the current CEO of GenEp.
GenEp is a funded company, having raised a total of $10.4M across 3 funding rounds to date.
GenEp was founded in 2021 in Charlottesville, United States, within the biotechnology sector. Therapeutics for epilepsy treatment are developed, with a focus on mutations in sodium and other ion channels. Rare genetic epilepsies and treatment-resistant forms are addressed through these targeted therapies. Operations center on creating solutions for unmet needs in epilepsy care.
GenEp's top competitors include Marinus Pharma, Arvelle Therapeutics and ORPHELIA Pharma.
GenEp has 5 investors. Key investors include University of Virginia, 3B Future Health Fund, Kids Connect Charitable Fund, Angelini Ventures, and PDI Ventures.